Skip to content
Back to search results

Drug Use Disorders Identification Test (DUDIT)

Introduced by
Berman, Bergman, Palmstierna, Schlyter
Year
2005
Type
Self-report
Family
substance-use-screening
Font size

What does it do?

The DUDIT is a brief, gender-sensitive screening instrument designed to identify individuals with harmful or hazardous drug use patterns across a wide range of substances.

Developed by Berman and colleagues in 2005, it serves as a primary care and public health screening tool to detect drug-related problems before they escalate to dependence or disorder. The DUDIT is freely available and has been validated in multiple languages and settings.

The intuition behind the method

The DUDIT measures the frequency, consequences, and behavioral indicators of drug use, capturing both the quantity and patterns of substance consumption. It is grounded in the World Health Organization's (WHO) conceptual framework for substance use disorders, which emphasizes early identification and intervention across a continuum from hazardous use to dependence. The test acknowledges that drug use patterns vary by gender, using separate cutoff scores for men and women to improve detection sensitivity and reduce false positives.

History

The DUDIT was developed by Berman and colleagues in the Department of Clinical Neuroscience at the Karolinska Institute in Sweden and published in the European Addiction Research journal in 2005. The instrument was derived from the WHO ASSIST (Alcohol, Smoking and Substance Involvement Screening Test) and adapted to create a stand-alone, brief screening tool specifically for drug use. The DUDIT has been translated into multiple languages and has been validated in Swedish criminal justice populations, detoxification facilities, and community samples. It is freely available for clinical and research use without licensing restrictions.

When to use it

The DUDIT is appropriate for use in primary care, addiction medicine clinics, emergency departments, correctional facilities, occupational health services, and research settings where rapid screening for harmful drug use is needed. It is particularly useful for identifying individuals across a broad spectrum of substances (cannabis, amphetamines, opioids, cocaine, hallucinogens, inhalants, etc.) and for monitoring outcomes in treatment-seeking populations. The DUDIT is less suitable for diagnostic confirmation or severity staging; clinical interview and additional structured assessments are necessary for those purposes.

Limitations and considerations

  • Screening instrument, not diagnostic; cannot establish specific substance use disorder diagnoses
  • May miss individuals with subtle or early-stage problematic use if consequences are not yet apparent
  • Performance varies across substances; less sensitive for some drug classes than others
  • Depends on self-report and may be subject to underreporting or minimization, particularly in criminal justice contexts

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Brief and free-to-use screening instrument requiring minimal training or resources
  • Gender-sensitive cutoff scores improve detection accuracy across male and female populations
  • Covers multiple dimensions of drug use (frequency, consequences, withdrawal, social impact)
  • Validated in diverse settings including criminal justice, treatment facilities, and community samples
  • Demonstrated sensitivity and specificity for identifying harmful drug use across multiple substance classes

Applications

  • Primary care screening to identify at-risk individuals for opportunistic brief intervention or referral to addiction treatment
  • Emergency department rapid assessment to inform triage and discharge planning in patients presenting with acute intoxication or overdose
  • Criminal justice and correctional settings for risk stratification, treatment allocation, and re-entry planning
  • Research studies investigating prevalence of harmful drug use in community or clinical samples, or evaluating intervention effectiveness
  • Occupational health and workplace screening to protect worker safety in safety-sensitive industries

How it works

How it works

1

The DUDIT consists of 11 items covering the frequency of drug use, frequency of intoxication, maximum amount used in a single occasion, frequency of heavy use, duration of drug use, frequency of intravenous (IV) drug use, experience of withdrawal symptoms, experience of health, social, legal, or financial problems related to drug use, and whether close friends or family members have expressed concern about the respondent's drug use. Each item is rated on a 5-point scale (0–4), with specific anchors (Never, Once or twice, Monthly, Weekly, Daily or almost daily). The respondent completes the measure in approximately 3–5 minutes. No formal training is required to administer the DUDIT, making it suitable for use in primary care, emergency departments, criminal justice settings, and community-based programs.

Formula
11 items rated on a 5-point Likert scale (0 = Never, 1 = Once or twice, 2 = Monthly, 3 = Weekly, 4 = Daily or almost daily)
2

All 11 items are summed to produce a total score ranging from 0 to 44. Gender-specific cutoff scores are applied: for males, a score of 6 or higher indicates harmful or hazardous drug use; for females, a score of 2 or higher indicates harmful or hazardous drug use. The lower female cutoff reflects evidence that women experience adverse consequences of drug use at lower consumption levels than men. No reverse scoring is required.

Formula
Sum all item responses. Total range 0–44. Men ≥6 = harmful drug use; Women ≥2 = harmful drug use.
3

A DUDIT score at or above the gender-specific cutoff suggests the individual meets criteria for harmful or hazardous drug use and warrants further assessment for substance use disorder. Scores below the cutoff do not rule out a substance use disorder but indicate that drug use is not currently causing documented harm. The instrument is designed as a screening tool, not a diagnostic instrument; positive screens should be followed by comprehensive clinical assessment, including substance-specific histories, mental health comorbidity, and functional impairment.

Formula
Scores ≥6 (men) or ≥2 (women) indicate harmful or hazardous drug use. Score <6 (men) or <2 (women) = no evidence of problem use.

Common pitfalls

  • Using DUDIT as a sole diagnostic tool without follow-up clinical assessment; positive screens require comprehensive evaluation
  • Applying identical cutoff scores across genders, which reduces sensitivity in female populations
  • Failing to account for cultural, occupational, or contextual factors that may influence substance use patterns
  • Misinterpreting a negative screen as definitive evidence of no substance use problem; serial screening or clinical judgment may be warranted

Frequently asked questions

Can the DUDIT be used to diagnose substance use disorder?

No. The DUDIT is a screening instrument designed to identify harmful or hazardous drug use, not to diagnose substance use disorders. A positive DUDIT screen indicates need for further clinical assessment, including comprehensive history, DSM-5 criteria evaluation, and assessment of consequences across life domains.

Why are the cutoff scores different for men and women?

Research shows that women experience greater harm and social consequences from drug use at lower consumption levels compared to men, due to physiological, psychological, and social factors. The gender-specific cutoffs (≥6 for men, ≥2 for women) optimize sensitivity and specificity in each population.

How long does it take to administer the DUDIT?

The DUDIT takes approximately 3–5 minutes to complete as a self-report measure, or 5–10 minutes if administered by a clinician in interview format.

Is the DUDIT free and available for use?

Yes, the DUDIT is in the public domain and is freely available for clinical, research, and training use. No permission or licensing fee is required.

Can the DUDIT be used to assess severity of substance use disorder?

The DUDIT is not designed for severity assessment. It identifies the presence or absence of harmful drug use above a defined threshold. For severity staging and treatment planning, use dedicated instruments such as the ASAM Criteria or supplementary addiction severity measures.

What substances does the DUDIT cover?

The DUDIT assesses use across a broad range of illicit and non-medical drugs, including cannabis, amphetamines, cocaine, opioids, benzodiazepines, hallucinogens, and inhalants. It does not include alcohol or tobacco; use AUDIT or Fagerstrom scales for those substances.

Related methods

Sources

  1. Berman, A. H., Bergman, H., Palmstierna, T., & Schlyter, F. (2005). Evaluation of the Drug Use Disorder Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. European Addiction Research, 11(1), 22–31.

    Open DOI reference
    Copied.